Moderna (MRNA) Stock Price Today—Real Time Charts and Quotes

Q: What are the 52-week high and low prices for Moderna (MRNA)?

MRNA has a 52-week high of $59.88 and a 52-week low of $22.28, with the current price at $52.88.

Q: What is the price-to-earnings (P/E) ratio of Moderna (MRNA)? What does it indicate?

The current P/E ratio (TTM) of MRNA is -4.065063784549964, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of Moderna (MRNA)?

Moderna (MRNA) currently has a market cap of approximately $21.56B.

Q: What is the most recent quarterly earnings per share (EPS) for Moderna (MRNA)?

Moderna (MRNA)'s diluted earnings per share (Diluted EPS) is -8.086075949367089. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Moderna (MRNA) now?

As of now, MRNA is trading at $52.88, with a P/E ratio of -4.065063784549964 and a diluted EPS of -8.086075949367089. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Moderna's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Moderna (MRNA)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Moderna (MRNA) stock?

You can buy Moderna (MRNA) through Gate. Sign up for a Gate account and complete identity verification, then go to the Moderna trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$52.88

-$3.48(-6.17%)

*Data last updated: 2026-05-11 17:09 (UTC+8)

As of 2026-05-11 17:09, Moderna (MRNA) is priced at $52.88, with a total market cap of $21.56B, a P/E ratio of -4.06, and a dividend yield of 0.00%. Today, the stock price fluctuated between $52.70 and $59.88. The current price is 0.34% above the day's low and 11.69% below the day's high, with a trading volume of 20.92M. Over the past 52 weeks, MRNA has traded between $22.28 to $59.88, and the current price is -11.69% away from the 52-week high.

MRNA Key Stats

Yesterday's Close$48.54

Market Cap$21.56B

Volume20.92M

P/E Ratio-4.06

Dividend Yield (TTM)0.00%

Diluted EPS (TTM)8.09

Net Income (FY)-$2.82B

Revenue (FY)$1.94B

Earnings Date2026-07-31

EPS Estimate2.09

Revenue Estimate$98.29M

Shares Outstanding444.27M

Beta (1Y)1.056

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

SectorHealthcare

IndustryBiotechnology

CEOStéphane Bancel

HeadquartersCambridge,MA,US

Official Websitehttps://www.modernatx.com

Employees (FY)4.70K

Average Revenue (1Y)$413.61K

Net Income per Employee-$600.42K

Learn More about Moderna (MRNA)

Gate Learn Articles

BIO Protocol Founder Explains DeSci and Announces Three Upcoming Projects on LaunchpadBIO aims to assist scientists, patients, and biotech founders in building on-chain scientific communities, offering support in areas such as tokenomics design, community development, funding, and liquidity. Upcoming projects on BIO Launchpad include Curetopia, Long COVID Labs, and Quantum Biology DAO. 2024-11-27

Moderna (MRNA) FAQ

What's the stock price of Moderna (MRNA) today?

Moderna (MRNA) is currently trading at $52.88, with a 24h change of -6.17%. The 52-week trading range is $22.28–$59.88.

What are the 52-week high and low prices for Moderna (MRNA)?

What is the price-to-earnings (P/E) ratio of Moderna (MRNA)? What does it indicate?

What is the market cap of Moderna (MRNA)?

What is the most recent quarterly earnings per share (EPS) for Moderna (MRNA)?

Should you buy or sell Moderna (MRNA) now?

What factors can affect the stock price of Moderna (MRNA)?

How to buy Moderna (MRNA) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.